Phase III clinical trial to evaluate the efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared to a carrier cream in adolescents 12 to 17 years of age with moderate to severe chronic hand eczema.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: LEO PHARMA A/S
- Phase: III
- Execution start: 27/06/2022
- End of execution: 30/10/2023
- IP: FRANCISCO JOSE NAVARRO TRIVIÑO
